• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ETHICON INC. GYNECARE TVT RETROPUBIC SYSTEM; MESH, SURGICAL, SYNTHETIC, UROGYNECOLOGIC

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ETHICON INC. GYNECARE TVT RETROPUBIC SYSTEM; MESH, SURGICAL, SYNTHETIC, UROGYNECOLOGIC Back to Search Results
Catalog Number 810041B
Device Problem Material Erosion (1214)
Patient Problems Erosion (1750); Unspecified Infection (1930); Internal Organ Perforation (1987); Pain (1994); Other (for use when an appropriate patient code cannot be identified) (2200); Surgical procedure (2357)
Event Type  Injury  
Event Description
It was reported by an attorney that the patient underwent that a patient underwent sling procedure on (b)(6) 2011.It was reported that she experienced pain, erosion of her internal bodily tissue and other injuries following the procedure.It was reported that the patient has undergone multiple surgeries and revisionary procedures.No additional information was provided.
 
Manufacturer Narrative
(b)(4).Conclusion: no conclusion can be drawn at this time.Should additional information be obtained, a supplemental 3500a form will be submitted accordingly.In addition, a review of the batch manufacturing records was conducted and the batch met all finished goods release criteria.(b)(4).Total number of events - (b)(4).Gynecare tvt - 203.Gynecare tvt abrevo continence system - (b)(4).Gynecare tvt exact continence system - (b)(4).Gynecare tvt obturator system - (b)(4).Gynecare tvt retropubic system - (b)(4).Gynecare tvt-aa abdominal - (b)(4).
 
Manufacturer Narrative
The indication for procedure was stress urinary incontinence.It was reported that following insertion the patient experienced pain, infection, urinary problems, organ perforation, and recurrence.(b)(4).
 
Manufacturer Narrative
(b)(4).
 
Manufacturer Narrative
(b)(4).
 
Manufacturer Narrative
(b)(4).
 
Manufacturer Narrative
(b)(4).
 
Manufacturer Narrative
(b)(4).Ethicon mdr summary reporting exemption (b)(4).Reporting period (b)(6) 2014.
 
Manufacturer Narrative
(b)(4).Reporting period (b)(4) 2014.
 
Manufacturer Narrative
(b)(4).
 
Manufacturer Narrative
(b)(4).Reporting period october 1 2014 through november 30, 2014.
 
Manufacturer Narrative
(b)(4).
 
Manufacturer Narrative
(b)(4).
 
Manufacturer Narrative
(b)(4).
 
Manufacturer Narrative
(b)(4).
 
Manufacturer Narrative
(b)(4).Reporting period october 1 2014 through november 30, 2014.
 
Manufacturer Narrative
(b)(4).
 
Manufacturer Narrative
(b)(4).
 
Manufacturer Narrative
Date sent to the fda: 12/20/2017.Ethicon mdr summary reporting exemption (b)(4).Reporting period (b)(4) 2014 through (b)(4) 2014.
 
Manufacturer Narrative
Ethicon mdr summary reporting exemption (b)(4).Reporting period october 1 2014 through november 30, 2014.
 
Manufacturer Narrative
Ethicon mdr summary reporting exemption (b)(4).Reporting period october 1 2014 through november 30, 2014.
 
Manufacturer Narrative
Ethicon mdr summary reporting exemption (b)(4).Reporting period october 1 2014 through november 30, 2014.
 
Manufacturer Narrative
Ethicon mdr summary reporting exemption (b)(4).Reporting period october 1 2014 through november 30, 2014.
 
Manufacturer Narrative
Date sent to fda: 12/26/2018.Ethicon mdr summary reporting exemption e2013037.Reporting period october 1 2014 through november 30, 2014.
 
Manufacturer Narrative
Date sent to fda: 2/12/2019.Ethicon mdr summary reporting exemption e2013037.Reporting period october 1, 2014 through november 30, 2014.
 
Manufacturer Narrative
Date sent to fda: 04/24/2019.Ethicon mdr summary reporting exemption e2013037.Reporting period october 1, 2014 through november 30, 2014.
 
Manufacturer Narrative
Date sent to the fda: 10/28/2019.Ethicon mdr summary reporting exemption e2013037.Reporting period october 1 2014 through november 30, 2014.
 
Manufacturer Narrative
Date sent to fda: 06/23/2020.Ethicon mdr summary reporting exemption e2013037.Reporting period october 1, 2014 through november 30, 2014.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
GYNECARE TVT RETROPUBIC SYSTEM
Type of Device
MESH, SURGICAL, SYNTHETIC, UROGYNECOLOGIC
Manufacturer (Section D)
ETHICON INC.
p.o. box 151, route 22 west
somerville NJ 08876 0151
MDR Report Key4370478
MDR Text Key5286850
Report Number2210968-2014-12562
Device Sequence Number1
Product Code OTN
Combination Product (y/n)N
PMA/PMN Number
K012628
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Invalid Data
Type of Report Initial,Followup,Followup,Followup,Followup
Report Date 09/04/2014
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date02/28/2014
Device Catalogue Number810041B
Device Lot Number3500111
Was Device Available for Evaluation? Yes
Was the Report Sent to FDA? No
Initial Date Manufacturer Received 09/03/2014
Initial Date FDA Received12/30/2014
Supplement Dates Manufacturer ReceivedNot provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
09/03/2014
09/03/2014
09/03/2014
09/03/2014
09/03/2014
09/03/2014
09/03/2014
10/26/2018
12/26/2018
02/12/2019
04/24/2019
10/28/2019
06/23/2020
Supplement Dates FDA Received02/24/2015
04/29/2015
06/22/2015
10/27/2015
12/21/2015
02/23/2016
04/21/2016
06/21/2016
08/23/2016
10/26/2016
12/19/2016
02/23/2017
04/19/2017
06/27/2017
08/28/2017
10/23/2017
12/20/2017
02/27/2018
04/18/2018
06/21/2018
08/16/2018
10/28/2018
12/26/2018
02/12/2019
04/24/2019
10/28/2019
06/23/2020
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age62 YR
-
-